(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 31.5MM | +1% |
Gross Profit | 16.8MM | -6% |
Cost Of Revenue | 14.8MM | +9% |
Operating Income | -16.9MM | +23% |
Operating Expenses | 33.7MM | +7% |
Net Income | -12.4MM | +60% |
R&D | 7MM | -3% |
G&A | 24.2MM | +2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
BILLERICA, Mass., March 04, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effec
It's been a good week for Quanterix Corporation ( NASDAQ:QTRX ) shareholders, because the company has just released its...
Quanterix Corporation (NASDAQ:QTRX) Q4 2023 Earnings Call Transcript February 29, 2024 Quanterix Corporation misses on earnings expectations. Reported EPS is $-0.33 EPS, expectations were $-0.28. Quanterix Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]
Quanterix ( NASDAQ:QTRX ) Full Year 2023 Results Key Financial Results Revenue: US$122.4m (up 16% from FY 2022). Net...
Q4 2023 Quanterix Corp Earnings Call
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -17.86% and 13.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BILLERICA, Mass., February 29, 2024--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.